Product Launches

Lupin Launches Metformin, A Generic Diabetes Drug in the US

Company Report

 NEW DELHI: Drug manufacturer Lupin Pharmaceuticals Inc. recently announced the launch of metformin drug. Metformin is a generic copy of Glumetza which is a diabetes drug. Metformin would be launched in the US market. A First-to-File (FTF) product, Lupin Pharmaceuticals Inc. will be charged 15% to 20% lower and will have 180 days of marketing exclusivity by the USFDA (Food and Drug Administration). 

The company launched its metformin HCl ER Tablets, 500 mg and 1000 mg to promote a similar generic drug from Santarus Inc.’s named Glumetza HCl ER Tablets, 500 mg and 1000 mg. The drug is said to act as a helper in diet and exercise in order to develop glycemic control in adults that have type II diabetes mellitus. In the year 2015-16, Lupin has introduced 10 products in the United States and has received FDA approvals for 21. At present, Lupin has 35 FTF products. 

According to the recent report published by Pharmaion, “Global Insulin Market Opportunities, 2011 - 2021”, the prevalence of diabetes across the world is anticipated to be 366 million in 2030, according to World Health Organisation (WHO) Statistics. Insulin is a hormone released by the pancreas allowing your body to utilise sugar in form of glucose from carbohydrates present in the food or to store glucose for future use. Insulin helps keep blood sugar level from getting too high (hyperglycemia) or too low (hypoglycemia). In Type 1 diabetes, the body does not make enough insulin in the body and in type 3 diabetes, body cannot utilise insulin efficiently. High intake of unhealthy food, lack of any activity to burn calories and enhance metabolism, lethargic lifestyle, genetic pattern are the factors that may lead to diabetes and make an individual dependent of insulin.  


Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News